Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

被引：0
|
作者：
Lei Wen
Junjie Zhen
Changguo Shan
Mingyao Lai
Weiping Hong
Hui Wang
Mingting Ye
Yanying Yang
Shaoqun Li
Zhaoming Zhou
Jiangfen Zhou
Qingjun Hu
Juan Li
Xuwei Tian
Longhua Chen
Linbo Cai
Zhanhong Xie
Cheng Zhou
机构：
[1] Guangdong Sanjiu Brain Hospital,Department of Oncology
[2] The First People’s Hospital of Kashi Prefecture,Department of Radiation Oncology
[3] Southern Medical University,Department of Radiation Oncology, Nanfang Hospital
[4] The First Affiliated Hospital of Guangzhou Medical University,State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute for Respiratory Health
来源：
European Journal of Medical Research | / 28卷
关键词：
Osimertinib; EGFR; NSCLC; Leptomeningeal metastases (LM); Efficacy; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Karima Saboundji
    Jean-Bernard Auliac
    Maurice Pérol
    Géraldine François
    Henri Janicot
    Marie Marcq
    Catherine Dubos-Arvis
    Aldo Renault
    Florian Guisier
    Luc Odier
    Radj Gervais
    Christos Chouaïd
    Targeted Oncology, 2018, 13 : 501 - 507
  • [32] Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases
    Yang, T. Jonathan
    Wu, Abraham J.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 134 - 137
  • [33] Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review
    Papassotiriou, Ionas
    Kapogiannatos, Antonios
    Makatsoris, Christos
    Bakogeorgou, Sabrina
    Mantogiannakou, Ioanna
    Roussou, Emmanouela
    Souras, Georgios
    Liakas, Dimitris
    Sergentanis, Theodoros N.
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)
  • [34] Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
    Li, Huiying
    Yu, Tingting
    Huang, Mingmin
    Guo, Aibin
    Qian, Xiaoping
    Yin, Zhenyu
    ONCOTARGETS AND THERAPY, 2019, 12 : 7785 - 7790
  • [35] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
    Inomata, Minehiko
    Matsumoto, Masahiro
    Mizushima, Isami
    Hayashi, Kana
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Tobe, Kazuyuki
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2022, 16 (01)
  • [36] Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    Costa, Daniel B.
    Kobayashi, Susumu
    Tenen, Daniel G.
    Huberman, Mark S.
    LUNG CANCER, 2007, 58 (01) : 95 - 103
  • [37] An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
    Shi, Yue
    Jiang, Yingying
    Pan, Banzhou
    Wang, Zihan
    Li, Hang
    Ma, Yuxin
    Liu, Yilin
    He, Kang
    Wang, Zhitong
    Lu, Jianwei
    Shi, Meiqi
    Shen, Bo
    Zhou, Guoren
    Yin, Rong
    Rossi, Antonio
    Ito, Kentaro
    Santarpia, Mariacarmela
    Um, Sang-Won
    Wang, Xiaohua
    Chen, Cheng
    Feng, Jifeng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 817 - 831
  • [38] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
    Minehiko Inomata
    Masahiro Matsumoto
    Isami Mizushima
    Kana Hayashi
    Zenta Seto
    Kotaro Tokui
    Chihiro Taka
    Seisuke Okazawa
    Kenta Kambara
    Shingo Imanishi
    Toshiro Miwa
    Ryuji Hayashi
    Shoko Matsui
    Kazuyuki Tobe
    The Egyptian Journal of Bronchology, 2022, 16
  • [39] Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer
    Mizusaki, Shun
    Otsubo, Kohei
    Ninomiya, Toshifumi
    Arimura, Hidenobu
    Tsuchiya-Kawano, Yuko
    Inoue, Koji
    THORACIC CANCER, 2021, 12 (01) : 114 - 116
  • [40] DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models
    Chen, Zhen
    Vallega, Karin A.
    Wang, Dongsheng
    Quan, Zihan
    Fan, Songqing
    Wang, Qiming
    Leal, Ticiana
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (10):
12345